drugset / Trial / NCT05324592
Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A multicenter, randomized, double-blind, parallel-controlled phase I trial comparing the safety, pharmacokinetics and efficacy of 9MW0813 and aflibercept (EYLEA®) after a single dose in patients with diabetic macular edema (DME).
Timeline
- Start
- 2021-02-26
- Primary completion
- 2021-09-24
- Completion
- 2022-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 9MW0813 | Protein / enzyme biologic | 2 mg | Intravitreal |
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |